MA40993A - Dérivés de 4-oxo-3,4-dihydro-1,2,3-benzotriazine comme modulateurs gpr139 - Google Patents
Dérivés de 4-oxo-3,4-dihydro-1,2,3-benzotriazine comme modulateurs gpr139Info
- Publication number
- MA40993A MA40993A MA040993A MA40993A MA40993A MA 40993 A MA40993 A MA 40993A MA 040993 A MA040993 A MA 040993A MA 40993 A MA40993 A MA 40993A MA 40993 A MA40993 A MA 40993A
- Authority
- MA
- Morocco
- Prior art keywords
- gpr139
- modulators
- dihydro
- oxo
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La présente invention concerne un procédé permettant de traiter une maladie, un trouble ou un état pathologique associé à gpr139 à l'aide de composés de formule 1, lesquels composés sont des agonistes de gpr139, certains composés représentés par la formule 1, des compositions pharmaceutiques de ceux-ci, des procédés de fabrication desdits composés, et des intermédiaires de ceux-ci.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462082539P | 2014-11-20 | 2014-11-20 | |
US201562184729P | 2015-06-25 | 2015-06-25 | |
PCT/US2015/061607 WO2016081736A1 (fr) | 2014-11-20 | 2015-11-19 | 4-oxo-3,4-dihydro-1,2,3-benzotriazines utilisées en tant que modulateurs de gpr139 |
Publications (2)
Publication Number | Publication Date |
---|---|
MA40993A true MA40993A (fr) | 2017-09-27 |
MA40993B1 MA40993B1 (fr) | 2019-07-31 |
Family
ID=55022667
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA40993A MA40993B1 (fr) | 2014-11-20 | 2015-11-19 | Dérivés de 4-oxo-3,4-dihydro-1,2,3-benzotriazine comme modulateurs gpr139 |
Country Status (40)
Country | Link |
---|---|
US (5) | US9556130B2 (fr) |
EP (2) | EP3221298B1 (fr) |
JP (2) | JP6637501B2 (fr) |
KR (1) | KR102582021B1 (fr) |
CN (2) | CN107108531B (fr) |
AU (1) | AU2015349866B2 (fr) |
BR (1) | BR112017010311A2 (fr) |
CA (1) | CA2968242C (fr) |
CL (1) | CL2017001292A1 (fr) |
CO (1) | CO2017005959A2 (fr) |
CR (1) | CR20170275A (fr) |
CY (2) | CY1122613T1 (fr) |
DK (2) | DK3221298T3 (fr) |
DO (1) | DOP2017000120A (fr) |
EA (1) | EA033728B1 (fr) |
EC (1) | ECSP17038999A (fr) |
ES (2) | ES2897545T3 (fr) |
GE (1) | GEP20196961B (fr) |
HR (2) | HRP20212009T1 (fr) |
HU (2) | HUE044145T2 (fr) |
IL (1) | IL252311B (fr) |
JO (1) | JO3719B1 (fr) |
LT (2) | LT3536324T (fr) |
MA (1) | MA40993B1 (fr) |
MD (1) | MD3221298T2 (fr) |
MX (1) | MX2017006448A (fr) |
MY (1) | MY187423A (fr) |
NZ (1) | NZ732208A (fr) |
PE (1) | PE20170899A1 (fr) |
PH (1) | PH12017500920A1 (fr) |
PL (2) | PL3536324T3 (fr) |
PT (2) | PT3221298T (fr) |
RS (2) | RS62563B1 (fr) |
SG (1) | SG11201704002UA (fr) |
SI (2) | SI3536324T1 (fr) |
TN (1) | TN2017000196A1 (fr) |
TW (1) | TWI684590B (fr) |
UA (1) | UA120375C2 (fr) |
UY (1) | UY36406A (fr) |
WO (1) | WO2016081736A1 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3719B1 (ar) | 2014-11-20 | 2021-01-31 | Takeda Pharmaceuticals Co | 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139 |
US12042496B2 (en) | 2018-10-16 | 2024-07-23 | The University Of Florida Research Foundation, Incorporated | Methods related to opioid therapeutics |
WO2020097609A1 (fr) | 2018-11-09 | 2020-05-14 | Blackthorn Therapeutics, Inc. | Modulateurs du récepteur gpr139 |
CN114728975A (zh) | 2019-09-16 | 2022-07-08 | 武田药品工业株式会社 | 唑稠合的哒嗪-3(2h)-酮衍生物 |
WO2021127459A1 (fr) * | 2019-12-20 | 2021-06-24 | Blackthorn Therapeutics, Inc. | Modulateurs du récepteur gpr139 |
CA3177117A1 (fr) * | 2020-05-08 | 2021-11-11 | Amin Mohamed Kamel | Metabolites de benzotriazinone substitues d'un agoniste gpr139 |
JP2023541485A (ja) | 2020-09-21 | 2023-10-02 | 武田薬品工業株式会社 | 統合失調症のための処置 |
US11760788B2 (en) | 2021-03-02 | 2023-09-19 | Pathways Neuro Pharma, Inc. | Neuroreceptor compositions and methods of use |
CN116693545A (zh) * | 2022-03-01 | 2023-09-05 | 上海科技大学 | 噻吩并含氮杂环类化合物、含其的药物组合物、其制备方法及其应用 |
CN116693536A (zh) * | 2022-03-01 | 2023-09-05 | 上海科技大学 | 吡咯并三嗪酮类化合物、含其的药物组合物、其制备方法及其应用 |
CN117986183A (zh) * | 2022-10-28 | 2024-05-07 | 浙江友宁生物医药科技有限公司 | 一种gpr139受体激动剂、其制备方法及其应用 |
WO2024102802A1 (fr) * | 2022-11-11 | 2024-05-16 | Takeda Pharmaceutical Company Limited | Zélatriazine pour le traitement de la dépression |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3794726A (en) * | 1972-08-21 | 1974-02-26 | Uniroyal Inc | Inhibiting aggressive behavior with 1,2,3-benzotriazin-(3h)-one |
US4959368A (en) | 1986-02-24 | 1990-09-25 | Mitsui Petrochemical Industries Ltd. | Therapeutic agent for neurological diseases |
EP0315390B1 (fr) * | 1987-11-04 | 1994-07-20 | Beecham Group Plc | Composés nouveaux de 4-oxobenzotriazine et 4-oxoquinazoline |
US7582766B2 (en) | 2003-06-09 | 2009-09-01 | Boehringer Ingelheim International Gmbh | Inhibitors of papilloma virus |
AU2004261283B2 (en) | 2003-07-31 | 2008-05-01 | Irm, Llc | Bicyclic compounds and compositions as PDF inhibitors |
FR2875805B1 (fr) | 2004-09-27 | 2006-12-29 | Genfit S A | Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations |
TW200736227A (en) | 2005-12-23 | 2007-10-01 | Astrazeneca Ab | New compounds III |
TWI433839B (zh) | 2006-08-11 | 2014-04-11 | Neomed Inst | 新穎的苯并咪唑衍生物290 |
CN101641358A (zh) * | 2007-03-23 | 2010-02-03 | 霍夫曼-拉罗奇有限公司 | 氮杂-吡啶并嘧啶酮衍生物 |
CA2709784A1 (fr) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Procede permettant de modifier la duree de vie d'organismes eucaryotes |
WO2011138265A2 (fr) | 2010-05-03 | 2011-11-10 | Evotec Ag | Dérivés d'indole et d'indazole utilisés comme antagonistes du récepteur de l'orexine |
WO2014152917A2 (fr) | 2013-03-14 | 2014-09-25 | Janssen Pharmaceutica Nv | Ligands physiologiques pour gpr139 |
JO3719B1 (ar) * | 2014-11-20 | 2021-01-31 | Takeda Pharmaceuticals Co | 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139 |
-
2015
- 2015-11-18 JO JOP/2015/0282A patent/JO3719B1/ar active
- 2015-11-19 PL PL19152036T patent/PL3536324T3/pl unknown
- 2015-11-19 HR HRP20212009TT patent/HRP20212009T1/hr unknown
- 2015-11-19 CN CN201580071393.8A patent/CN107108531B/zh active Active
- 2015-11-19 CA CA2968242A patent/CA2968242C/fr active Active
- 2015-11-19 AU AU2015349866A patent/AU2015349866B2/en active Active
- 2015-11-19 DK DK15816275.0T patent/DK3221298T3/da active
- 2015-11-19 SI SI201531729T patent/SI3536324T1/sl unknown
- 2015-11-19 WO PCT/US2015/061607 patent/WO2016081736A1/fr active Application Filing
- 2015-11-19 MY MYPI2017701778A patent/MY187423A/en unknown
- 2015-11-19 JP JP2017526844A patent/JP6637501B2/ja active Active
- 2015-11-19 BR BR112017010311A patent/BR112017010311A2/pt active IP Right Grant
- 2015-11-19 RS RS20211398A patent/RS62563B1/sr unknown
- 2015-11-19 GE GEAP201514515A patent/GEP20196961B/en unknown
- 2015-11-19 PL PL15816275T patent/PL3221298T3/pl unknown
- 2015-11-19 SI SI201530772T patent/SI3221298T1/sl unknown
- 2015-11-19 TN TN2017000196A patent/TN2017000196A1/en unknown
- 2015-11-19 LT LTEP19152036.0T patent/LT3536324T/lt unknown
- 2015-11-19 NZ NZ732208A patent/NZ732208A/en unknown
- 2015-11-19 EP EP15816275.0A patent/EP3221298B1/fr active Active
- 2015-11-19 CR CR20170275A patent/CR20170275A/es unknown
- 2015-11-19 PE PE2017000866A patent/PE20170899A1/es unknown
- 2015-11-19 KR KR1020177016973A patent/KR102582021B1/ko active IP Right Grant
- 2015-11-19 HU HUE15816275A patent/HUE044145T2/hu unknown
- 2015-11-19 CN CN202010988947.3A patent/CN112062730B/zh active Active
- 2015-11-19 MD MDE20170117 patent/MD3221298T2/ro unknown
- 2015-11-19 PT PT15816275T patent/PT3221298T/pt unknown
- 2015-11-19 ES ES19152036T patent/ES2897545T3/es active Active
- 2015-11-19 ES ES15816275T patent/ES2734735T3/es active Active
- 2015-11-19 DK DK19152036.0T patent/DK3536324T3/da active
- 2015-11-19 RS RS20190776A patent/RS59078B1/sr unknown
- 2015-11-19 PT PT191520360T patent/PT3536324T/pt unknown
- 2015-11-19 US US14/946,194 patent/US9556130B2/en active Active
- 2015-11-19 LT LTEP15816275.0T patent/LT3221298T/lt unknown
- 2015-11-19 UA UAA201705041A patent/UA120375C2/uk unknown
- 2015-11-19 HU HUE19152036A patent/HUE057451T2/hu unknown
- 2015-11-19 TW TW104138295A patent/TWI684590B/zh active
- 2015-11-19 MX MX2017006448A patent/MX2017006448A/es unknown
- 2015-11-19 UY UY0001036406A patent/UY36406A/es not_active Application Discontinuation
- 2015-11-19 EP EP19152036.0A patent/EP3536324B1/fr active Active
- 2015-11-19 MA MA40993A patent/MA40993B1/fr unknown
- 2015-11-19 EA EA201791096A patent/EA033728B1/ru unknown
- 2015-11-19 SG SG11201704002UA patent/SG11201704002UA/en unknown
-
2016
- 2016-12-16 US US15/382,490 patent/US9770450B2/en active Active
-
2017
- 2017-05-12 DO DO2017000120A patent/DOP2017000120A/es unknown
- 2017-05-16 IL IL252311A patent/IL252311B/en active IP Right Grant
- 2017-05-18 PH PH12017500920A patent/PH12017500920A1/en unknown
- 2017-05-19 CL CL2017001292A patent/CL2017001292A1/es unknown
- 2017-06-16 CO CONC2017/0005959A patent/CO2017005959A2/es unknown
- 2017-06-20 EC ECIEPI201738999A patent/ECSP17038999A/es unknown
- 2017-08-22 US US15/683,589 patent/US10159677B2/en active Active
-
2018
- 2018-11-02 US US16/179,709 patent/US10561662B2/en active Active
-
2019
- 2019-06-03 HR HRP20191003TT patent/HRP20191003T1/hr unknown
- 2019-06-20 CY CY20191100646T patent/CY1122613T1/el unknown
- 2019-12-20 JP JP2019229837A patent/JP6918088B2/ja active Active
-
2020
- 2020-01-02 US US16/732,536 patent/US11173161B2/en active Active
-
2021
- 2021-12-17 CY CY20211101111T patent/CY1124929T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA40993A (fr) | Dérivés de 4-oxo-3,4-dihydro-1,2,3-benzotriazine comme modulateurs gpr139 | |
EA201650031A1 (ru) | Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1 | |
EA201791002A1 (ru) | Новые соединения, модулирующие fxr (nr1h4) | |
EA201692418A1 (ru) | Замещенные индазольные соединения в качестве irak4 ингибиторов | |
EA201691514A1 (ru) | Соединения | |
MA40302B1 (fr) | Dérivés de carbazole | |
BR112016024936A2 (pt) | moduladores de gpr40 à base de pirrolidina para tratamento de doenças como diabetes | |
PH12017500653A1 (en) | Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes | |
MA39335B1 (fr) | Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone | |
EA201791058A1 (ru) | Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4) | |
AU2016380190A8 (en) | Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof | |
CL2020001589A1 (es) | Proceso para la preparación de derivados de quinolina. | |
MA39171A1 (fr) | Dérivés d'hydroxy formamide et leur utilisation | |
NZ746906A (en) | Oxaborole esters and uses thereof | |
PE20160860A1 (es) | Derivados de etinil-imidazolidin-2,4-diona como moduladores de mglur 4 | |
CL2017000484A1 (es) | Compuestos de azetidiniloxifenilpirrolidina | |
MA39315A1 (fr) | Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique | |
EA202190272A1 (ru) | Дополнительно замещенные производные триазолохиноксалина | |
MA40366A (fr) | Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines | |
EA202190271A1 (ru) | Замещенные триазолохиноксалиновые производные | |
MA39337A1 (fr) | Modulateurs de pyrazines de gpr6 | |
EA201791643A1 (ru) | Средства визуализации для пэт | |
MA44503B1 (fr) | Composés de pyrrolotriazine en tant qu'inhibiteurs de tam | |
MA46307B1 (fr) | Composition et procédés pour moduler l'expression du facteur b du complément | |
MA35887B1 (fr) | Nouveaux dérivés morpholynyle utiles comme inhibiteurs de mogat-2 |